---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003436"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:05:00.825653+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics reports FY2022 net loss of $650.2M; exa-cel regulatory submissions complete in Europe

## Summary
- Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.
- R&D expenses for FY2022 were $461.6M, up from $340.6M in FY2021, driven by pipeline advancement.
- Net loss for FY2022 was $650.2M, compared to net income of $377.7M in FY2021, due to lower collaboration revenue.
- Regulatory submissions for exa-cel (CTX001) completed in Europe; U.S. BLA rolling submission on track for Q1 2023.
- Enrolling and dosing ongoing for CTX110 (CD19+ B-cell malignancies) and CTX130 (CD70+ T cell lymphomas); next-gen CAR T trials initiating.

## SEC filing metadata
- accession: 0000950170-23-003436
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/0000950170-23-003436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/crsp-20230221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003436
- JSON: https://secwatch.observer/filing/0000950170-23-003436.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003436.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On February 21, 2023, CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/0000950170-23-003436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.